Cases of antibiotic-resistant ‘super gonorrhea’ are rising rapidly according to the World Health Organization (WHO).

Gonorrhea is a common sexually transmitted infection that affects approximately 78 million people each year, with common symptoms including genital discharge and pain during urination.

For decades it has been effectively treated using common antibiotics, but a recent analysis of data from 77 countries shows that increased antibiotic resistance is making gonorrhea much harder to treat.

Widespread resistance to several antibiotics was identified, with some countries reporting cases of infections that were untreatable by any known antibiotic.    

More than ever, prevention is better than cure

Despite the urgent unmet need for new antibiotics for gonorrhea, few are currently in development. The situation was described as 'grim' by the director of the Global Antibiotic Research and Development Partnership.

With treatment becoming ever more challenging, interest in preventative strategies has increased. However, attempts to develop a gonococcal vaccine have so far been unsuccessful.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

A WHO action plan has recommended further vaccine research as a high priority, as effective vaccines are likely to be the only sustainable way to control the disease.

Meningitis B vaccine: a surprise source of protection

A recent retrospective analysis of 15-30 year olds vaccinated against meningitis B during an epidemic in New Zealand in the mid-2000s identified significantly reduced rates of gonorrhea.

This was the first report of any vaccine demonstrating a protective effect against gonorrhea. However, there were two major drawbacks, as the effectiveness of vaccine MeNZB was relatively modest at only 31% and it is also no longer in use.  

However, GlaxoSmithKline’s meningitis B vaccine Bexsero contains the same antigen as MeNZB, and the company has announced plans to investigate the drug’s potential for protecting against gonorrhea.

A timely intervention

With options for treatment dwindling, demand for an effective gonorrhea vaccine has never been greater.

Analysis suggests that even modest protective effects could have substantial public health benefits if immunisation rates are high.

The recent findings may not present an immediate solution to the gonorrhea public health crisis, but they will inform and advance much-needed vaccine research in the coming years.